PROJECT TITLE: Mulfistage Vectors (MSV) for Ovarian Cancer Therapeufics PROJECT SUMMARY: Because ovarian cancer is fifth leading cause of cancer deaths in women and a leading cause of death from gynecologic cancers in the United States, it is necessary to develop novel therapeufic agents and strategies beyond convenfional chemotherapy for the treatment of advanced ovarian cancer. Nanotechnology meets this necessity because of the possibility to develop novel therapeufics. Project 1 alms to demonstrate the feasibility for translafion of a novel biocompatible nano-delivery system for efficient in vivo siRNA and drug delivery to achieve control of tumor growth and angiogenesis for a prolonged period. Project 1 will use the innovafive "multi-stage" approach, using biodegradable porous silicon particles as a carrier of therapeufic nanoparticles, which will offer a paradigm shift from convenfional nanotechnology based drug delivery by improving unfavorable pharmacokinefics of nanoparticles. Additionally, Project 1 aims to monitor therapeufic responses. Project 1 presents how novel nanotechnologies offer unequaled solufions to such undisputable necessity. The investigators will develop nanochip technologies to establish proteomic profiles to effectively monitor therapeufic responses and complement these with the development of sensifive gold-gold nanoshells to image tumor microvasculature with superb resolufion to monitor tumor vasculature response to therapy. Moreover, the investigators will utilize core-crosslinked polymeric micelles to detect and image active apoptosis in vivo, indicative of response to most anti-cancer therapies. The proposed work will greatly contribute to fill the existing gap between discovery of basic cancer biology and nanotechnology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center Houston
United States
Zip Code
Cui, Min-Hui; Branch, Craig A; Cahill, Sean M et al. (2015) In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model. Magn Reson Med 74:1221-6
Bottsford-Miller, Justin; Choi, Hyun-Jin; Dalton, Heather J et al. (2015) Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res 21:602-10
Sun, Yan; Hu, Limei; Zheng, Hong et al. (2015) MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 235:25-36
Wen, Yunfei; Graybill, Whitney S; Previs, Rebecca A et al. (2015) Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21:448-59
Previs, Rebecca A; Coleman, Robert L; Harris, Adrian L et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res 21:955-61
Jaganathan, Hamsa; Mitra, Sucharita; Srinivasan, Srimeenakshi et al. (2014) Design and in vitro evaluation of layer by layer siRNA nanovectors targeting breast tumor initiating cells. PLoS One 9:e91986
Ozpolat, Bulent; Sood, Anil K; Lopez-Berestein, Gabriel (2014) Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66:110-6
Yang, Yong; Wolfram, Joy; Fang, Xiaohong et al. (2014) Polyarginine induces an antitumor immune response through binding to toll-like receptor 4. Small 10:1250-4
Tang, Lei; van de Ven, Anne L; Guo, Dongmin et al. (2014) Computational modeling of 3D tumor growth and angiogenesis for chemotherapy evaluation. PLoS One 9:e83962
Zhaorigetu, Siqin; Rodriguez-Aguayo, Cristian; Sood, Anil K et al. (2014) Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res 24:182-90

Showing the most recent 10 out of 153 publications